GSK reports that its HIV company ViiV Healthcare, which also counts Pfizer among its shareholders, today presented results from a Phase III trial.

According to the company, the long-acting injectable antiretroviral therapy (ART) for HIV, Cabenuva (cabotegravir + rilpivirine), demonstrated superior efficacy to daily oral therapy in maintaining viral load suppression.

According to Kimberly Smith, Head of R&D at ViiV Healthcare, these provisional data 'represent a remarkable result'.

Copyright (c) 2024 All rights reserved.